JP2023510349A5 - - Google Patents
Info
- Publication number
- JP2023510349A5 JP2023510349A5 JP2022542333A JP2022542333A JP2023510349A5 JP 2023510349 A5 JP2023510349 A5 JP 2023510349A5 JP 2022542333 A JP2022542333 A JP 2022542333A JP 2022542333 A JP2022542333 A JP 2022542333A JP 2023510349 A5 JP2023510349 A5 JP 2023510349A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- amino acid
- conjugate
- seq
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2026061557A JP2026117046A (ja) | 2020-01-09 | 2026-04-03 | ペプチド含有リンカーとの部位特異的抗体-薬物コンジュゲート |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062958916P | 2020-01-09 | 2020-01-09 | |
| US62/958,916 | 2020-01-09 | ||
| US202063040735P | 2020-06-18 | 2020-06-18 | |
| US63/040,735 | 2020-06-18 | ||
| PCT/US2021/012611 WO2021142199A1 (en) | 2020-01-09 | 2021-01-08 | Site specific antibody-drug conjugates with peptide-containing linkers |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026061557A Division JP2026117046A (ja) | 2020-01-09 | 2026-04-03 | ペプチド含有リンカーとの部位特異的抗体-薬物コンジュゲート |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023510349A JP2023510349A (ja) | 2023-03-13 |
| JP2023510349A5 true JP2023510349A5 (cg-RX-API-DMAC7.html) | 2024-01-19 |
| JP7846624B2 JP7846624B2 (ja) | 2026-04-15 |
Family
ID=74495099
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022542333A Active JP7846624B2 (ja) | 2020-01-09 | 2021-01-08 | ペプチド含有リンカーとの部位特異的抗体-薬物コンジュゲート |
| JP2026061557A Pending JP2026117046A (ja) | 2020-01-09 | 2026-04-03 | ペプチド含有リンカーとの部位特異的抗体-薬物コンジュゲート |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026061557A Pending JP2026117046A (ja) | 2020-01-09 | 2026-04-03 | ペプチド含有リンカーとの部位特異的抗体-薬物コンジュゲート |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11786605B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4087614A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7846624B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220124762A (cg-RX-API-DMAC7.html) |
| CN (1) | CN115884793A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021205312A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022013255A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3163833A1 (cg-RX-API-DMAC7.html) |
| IL (2) | IL326905A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022008437A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202140075A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021142199A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112022013255A2 (pt) | 2020-01-09 | 2022-09-06 | Mersana Therapeutics Inc | Conjugados anticorpo-fármaco específicos de sítio com ligantes contendo peptídeo |
| WO2022147532A1 (en) | 2021-01-04 | 2022-07-07 | Mersana Therapeutics, Inc. | B7h4-targeted antibody-drug conjugates and methods of use thereof |
| WO2023141856A1 (zh) * | 2022-01-27 | 2023-08-03 | 岩唐生物科技(杭州)有限责任公司 | 靶向cd3的多特异性抗体及其应用 |
| KR20250089528A (ko) * | 2022-10-18 | 2025-06-18 | 투불리스 게엠베하 | 신규한 napi2b 항체를 함유하는 신규한 항체 약물 접합체, 치료 방법 및 이의 용도 |
| WO2025248500A1 (en) | 2024-05-31 | 2025-12-04 | Janssen Biotech, Inc. | Antibody drug conjugates that target enpp3 |
| WO2026017107A1 (en) * | 2024-07-19 | 2026-01-22 | Primelink Biotherapeutics (Shenzhen) Co., Ltd. | Linker-polymer-drug conjugates |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| EP0563475B1 (en) | 1992-03-25 | 2000-05-31 | Immunogen Inc | Cell binding agent conjugates of derivatives of CC-1065 |
| US5763263A (en) | 1995-11-27 | 1998-06-09 | Dehlinger; Peter J. | Method and apparatus for producing position addressable combinatorial libraries |
| US20080070981A1 (en) | 2000-02-23 | 2008-03-20 | Henryk Borowy-Borowski | Water-soluble compositions of bioactive lipophilic compounds |
| HK1049997B (en) | 1999-11-24 | 2007-02-23 | Immunogen, Inc. | Cytotoxic agents comprising taxanes and their therapeutic use |
| AU767394C (en) | 1999-12-29 | 2005-04-21 | Immunogen, Inc. | Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use |
| US6333410B1 (en) | 2000-08-18 | 2001-12-25 | Immunogen, Inc. | Process for the preparation and purification of thiol-containing maytansinoids |
| US6441163B1 (en) | 2001-05-31 | 2002-08-27 | Immunogen, Inc. | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents |
| US6756397B2 (en) | 2002-04-05 | 2004-06-29 | Immunogen, Inc. | Prodrugs of CC-1065 analogs |
| US6534660B1 (en) | 2002-04-05 | 2003-03-18 | Immunogen, Inc. | CC-1065 analog synthesis |
| US6596757B1 (en) | 2002-05-14 | 2003-07-22 | Immunogen Inc. | Cytotoxic agents comprising polyethylene glycol-containing taxanes and their therapeutic use |
| AU2004204463B2 (en) | 2003-01-10 | 2009-02-12 | Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services National Institutes Of Health | Catalytic domains of beta(1,4)-galactosyltransferase I having altered donor and acceptor specificities, domains that promote in vitro protein folding, and methods for their use |
| US7276497B2 (en) | 2003-05-20 | 2007-10-02 | Immunogen Inc. | Cytotoxic agents comprising new maytansinoids |
| US8431558B2 (en) | 2004-11-01 | 2013-04-30 | The Regents Of The University Of California | Compositions and methods for modification of biomolecules |
| US7807619B2 (en) | 2004-11-01 | 2010-10-05 | The Regents Of The University Of California | Compositions and methods for modification of biomolecules |
| US8367065B2 (en) | 2006-09-15 | 2013-02-05 | Enzon Pharmaceuticals, Inc. | Targeted polymeric prodrugs containing multifunctional linkers |
| TW200902708A (en) | 2007-04-23 | 2009-01-16 | Wyeth Corp | Methods of protein production using anti-senescence compounds |
| EP2250201B1 (en) | 2008-01-29 | 2014-04-30 | Ludwig Institute for Cancer Research Ltd. | Membrane transporter napi2b (slc34a2) epitope for antibody therapy, antibodies directed thereto, and target for cancer therapy |
| WO2009102820A2 (en) | 2008-02-11 | 2009-08-20 | Government Of The U.S A., As Represented By The Secretary, Department Of Health And Human Services | Modified sugar substrates and methods of use |
| US8859629B2 (en) | 2010-04-27 | 2014-10-14 | Synaffix B.V. | Fused cyclooctyne compounds and their use in metal-free click reactions |
| GB201115841D0 (en) | 2011-09-13 | 2011-10-26 | Genovis Ab | Protein and method |
| US9199237B2 (en) * | 2012-09-04 | 2015-12-01 | Michael Baumgartner | Automated well plate |
| EA201590622A1 (ru) | 2012-10-16 | 2015-10-30 | Эндосайт, Инк. | Конъюгаты для доставки лекарственного средства, содержащие не встречающиеся в природе аминокислоты, и способы применения |
| HRP20180268T4 (hr) | 2012-10-23 | 2026-03-27 | Synaffix B.V. | Modificirano antitijelo, konjugat antitijela i postupak za njihovu pripremu |
| EP3004062B1 (en) | 2013-05-24 | 2017-07-19 | SynAffix B.V. | Substituted azadibenzocyclooctyne compounds and their use in metal-free click reactions |
| WO2015057065A1 (en) | 2013-10-14 | 2015-04-23 | Synaffix B.V. | Glycoengineered antibody, antibody-conjugate and methods for their preparation |
| PT3057585T (pt) | 2013-10-15 | 2020-10-21 | Seagen Inc | Fármaco-ligadores peguilados para farmacocinética melhorada de conjugados de fármaco-ligando |
| CA2943984A1 (en) * | 2014-06-12 | 2015-12-17 | Halliburton Energy Services, Inc. | Determination of substance presence, identity and/or level in vessels |
| TWI695011B (zh) | 2014-06-18 | 2020-06-01 | 美商梅爾莎納醫療公司 | 抗her2表位之單株抗體及其使用之方法 |
| EP3177633B1 (en) | 2014-08-04 | 2022-07-20 | SynAffix B.V. | Process for the modification of a glycoprotein using a beta-(1,4)-n-acetylgalactosaminyltransferase or a mutant thereof |
| CN107810273B (zh) | 2015-04-23 | 2022-09-27 | 西纳福克斯股份有限公司 | 用为或衍生自β-(1,4)-N-乙酰半乳糖胺转移酶的糖基转移酶修饰糖蛋白的方法 |
| EP3414328B1 (en) | 2016-02-08 | 2024-01-10 | Synaffix B.V. | Enzymes for trimming of glycoproteins |
| WO2017137457A1 (en) | 2016-02-08 | 2017-08-17 | Synaffix B.V. | Antibody-conjugates with improved therapeutic index for targeting cd30 tumours and method for improving therapeutic index of antibody-conjugates |
| WO2017137458A1 (en) | 2016-02-08 | 2017-08-17 | Synaffix B.V. | Antibody-conjugates with improved therapeutic index for targeting cd30 tumours and method for improving therapeutic index of antibody-conjugates |
| BR112018068461A2 (pt) | 2016-03-15 | 2019-01-22 | Mersana Therapeutics Inc | conjugado, composição farmacêutica, métodos para preparação de um conjugado e para alívio de um sintoma de um câncer. |
| US20180098269A1 (en) * | 2016-04-25 | 2018-04-05 | Telefonaktiebolaget Lm Ericsson (Publ) | System Information Configuration Update in a Wireless Communication Network |
| US11135307B2 (en) * | 2016-11-23 | 2021-10-05 | Mersana Therapeutics, Inc. | Peptide-containing linkers for antibody-drug conjugates |
| TW201834697A (zh) | 2017-02-28 | 2018-10-01 | 美商梅爾莎納醫療公司 | Her2標靶抗體-藥物結合物之組合療法 |
| EP3685166A2 (en) | 2017-09-20 | 2020-07-29 | Mersana Therapeutics, Inc. | Compositions and methods for predicting response to napi2b-targeted therapy |
| BR112022013255A2 (pt) | 2020-01-09 | 2022-09-06 | Mersana Therapeutics Inc | Conjugados anticorpo-fármaco específicos de sítio com ligantes contendo peptídeo |
| WO2022147532A1 (en) * | 2021-01-04 | 2022-07-07 | Mersana Therapeutics, Inc. | B7h4-targeted antibody-drug conjugates and methods of use thereof |
-
2021
- 2021-01-08 BR BR112022013255A patent/BR112022013255A2/pt unknown
- 2021-01-08 MX MX2022008437A patent/MX2022008437A/es unknown
- 2021-01-08 US US17/144,378 patent/US11786605B2/en active Active
- 2021-01-08 AU AU2021205312A patent/AU2021205312A1/en active Pending
- 2021-01-08 CN CN202180022159.1A patent/CN115884793A/zh active Pending
- 2021-01-08 JP JP2022542333A patent/JP7846624B2/ja active Active
- 2021-01-08 TW TW110100793A patent/TW202140075A/zh unknown
- 2021-01-08 IL IL326905A patent/IL326905A/en unknown
- 2021-01-08 EP EP21702822.4A patent/EP4087614A1/en active Pending
- 2021-01-08 KR KR1020227027101A patent/KR20220124762A/ko active Pending
- 2021-01-08 CA CA3163833A patent/CA3163833A1/en active Pending
- 2021-01-08 WO PCT/US2021/012611 patent/WO2021142199A1/en not_active Ceased
-
2022
- 2022-06-27 IL IL294321A patent/IL294321B2/en unknown
-
2023
- 2023-08-30 US US18/458,397 patent/US20240148887A1/en active Pending
-
2026
- 2026-04-03 JP JP2026061557A patent/JP2026117046A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI847992B (zh) | 抗體-藥物結合物之有效的製造方法 | |
| JP2022095908A5 (cg-RX-API-DMAC7.html) | ||
| US20260139074A1 (en) | Combination of antibody-drug conjugate and tubulin inhibitor | |
| IL302078A (en) | Anti-CCR8 monoclonal antibodies and their uses | |
| JP2024501894A5 (cg-RX-API-DMAC7.html) | ||
| JP2020509027A5 (cg-RX-API-DMAC7.html) | ||
| JP2023539715A5 (cg-RX-API-DMAC7.html) | ||
| JPWO2021177438A5 (cg-RX-API-DMAC7.html) | ||
| JP2022519273A5 (cg-RX-API-DMAC7.html) | ||
| JP2023545096A5 (cg-RX-API-DMAC7.html) | ||
| EP3804764A1 (en) | Treatment of her2-mutated cancer by administering anti-her2 antibody-drug conjugate | |
| JP2023548051A5 (cg-RX-API-DMAC7.html) | ||
| US20260115306A1 (en) | Combination of anti-cdh6 antibody-drug conjugate and vegf inhibitor | |
| CN114450025A (zh) | 使用包含多重酪氨酸激酶抑制剂和免疫检查点抑制剂的组合治疗癌症 | |
| JP2025517908A5 (cg-RX-API-DMAC7.html) | ||
| US20260021194A1 (en) | Antibody drug conjugate (adc) targeting nectin 4 and comprising an exatecan payload | |
| JP2024536383A5 (cg-RX-API-DMAC7.html) | ||
| CN112996540A (zh) | 一种c-Met ADC在制备治疗c-Met激酶抑制剂耐药的疾病的药物中的用途 | |
| AU2024316626A1 (en) | Anti-ror1 protein antibody and conjugate thereof | |
| JP2020507569A5 (cg-RX-API-DMAC7.html) | ||
| JPWO2022019259A5 (cg-RX-API-DMAC7.html) | ||
| IL300030A (en) | Combination of an anti-2HER drug-antibody conjugate with a dimerization suppressor | |
| WO2026098619A1 (zh) | 一种egfr×her3双特异性抗体药物偶联物、其制备方法和应用 | |
| WO2025164597A1 (ja) | 抗her2抗体-薬物コンジュゲートと他剤との組み合わせ | |
| TW202535465A (zh) | 抗cd147抗體與其他抗腫瘤劑之組合 |